J AAPOS
According to a recent article from Regulatory Affairs Professionals Society (RAPS), an official at the FDA confirmed that warning letters issued by the Center for Drug Evaluation and Research (CDER) rose by a whopping 50% in fiscal year 2025 a sharp signal that regulators are intensifying scrutiny across multiple fronts
Signs youre managing well enough to continue: Youre drinking fluids regularly without vomiting You can eat small, frequent meals or snacks Your symptoms are improving or stable, not worsening Youre able to rest and recover at home No signs of dehydration (dark urine, dizziness, rapid heartbeat) Consulting Your Healthcare Provider Before making any decision to skip doses, contact your healthcare provider
L-Carnitine forms are usually higher-dose materials, and many are hygroscopic, which can reduce flowability, increase clumping risk, and create capsule-weight variation under poor humidity control
What's missing: No human pharmacokinetic data No human safety data No optimal dose for humans (mouse 20mg/kg = ~150mg in a 75kg human if dose-equivalent, but mouse-to-human scaling for small molecules is unreliable) No drug interaction data No long-term safety data Buyers in this category are doing biohacker-tier self-experimentation with limited data
And the muscle masses the way to handle that problem is to be physically active